Michael Dechant

2.3k total citations
40 papers, 1.8k citations indexed

About

Michael Dechant is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Michael Dechant has authored 40 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Radiology, Nuclear Medicine and Imaging, 18 papers in Immunology and 14 papers in Molecular Biology. Recurrent topics in Michael Dechant's work include Monoclonal and Polyclonal Antibodies Research (30 papers), Glycosylation and Glycoproteins Research (14 papers) and T-cell and B-cell Immunology (13 papers). Michael Dechant is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (30 papers), Glycosylation and Glycoproteins Research (14 papers) and T-cell and B-cell Immunology (13 papers). Michael Dechant collaborates with scholars based in Germany, Netherlands and United States. Michael Dechant's co-authors include Thomas Valerius, Jan G. J. van de Winkel, Matthias Peipp, Thomas Beyer, Paul W.H.I. Parren, Tanja Schneider‐Merck, Roland Repp, Stefan Lohse, Jeroen J. Lammerts van Bueren and Sven Berger and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Michael Dechant

40 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Dechant Germany 25 1.0k 982 664 590 168 40 1.8k
Hans Ulrichts Belgium 20 400 0.4× 703 0.7× 420 0.6× 143 0.2× 209 1.2× 30 1.7k
Randall J. Brezski United States 23 963 0.9× 917 0.9× 769 1.2× 551 0.9× 110 0.7× 32 2.0k
Yvonne A. Efebera United States 27 185 0.2× 1.4k 1.4× 1.0k 1.6× 1.6k 2.6× 170 1.0× 150 3.0k
DA Vallera United States 23 140 0.1× 1.1k 1.1× 249 0.4× 329 0.6× 165 1.0× 45 1.7k
Kathy Schiffman United States 16 610 0.6× 1.4k 1.4× 674 1.0× 980 1.7× 32 0.2× 28 1.8k
Paulo Vidal Campregher Brazil 12 133 0.1× 950 1.0× 323 0.5× 569 1.0× 188 1.1× 57 1.7k
Sandra Croockewit Netherlands 16 81 0.1× 845 0.9× 517 0.8× 651 1.1× 94 0.6× 34 1.4k
Martha Hayden-Ledbetter United States 13 160 0.2× 763 0.8× 381 0.6× 299 0.5× 80 0.5× 18 1.5k
Robert Wasserman United States 18 314 0.3× 945 1.0× 545 0.8× 344 0.6× 261 1.6× 35 1.8k
Katrin Moser Germany 14 237 0.2× 923 0.9× 363 0.5× 171 0.3× 146 0.9× 15 1.6k

Countries citing papers authored by Michael Dechant

Since Specialization
Citations

This map shows the geographic impact of Michael Dechant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Dechant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Dechant more than expected).

Fields of papers citing papers by Michael Dechant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Dechant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Dechant. The network helps show where Michael Dechant may publish in the future.

Co-authorship network of co-authors of Michael Dechant

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Dechant. A scholar is included among the top collaborators of Michael Dechant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Dechant. Michael Dechant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dechant, Michael, et al.. (2024). Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal study. Nordic Studies on Alcohol and Drugs. 41(6). 640–655. 2 indexed citations
2.
Dechant, Michael, et al.. (2022). A meta-analysis on the effects of incarceration-based opioid substitution treatment. Medicine Science and the Law. 63(1). 53–60. 10 indexed citations
3.
Derer, Stefanie, Sven Berger, Tanja Schneider‐Merck, et al.. (2012). Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBPβ-Dependent Suppression of EGFR Expression. Neoplasia. 14(3). 190–IN7. 18 indexed citations
4.
Repp, Roland, Christian Kellner, Dalia Akramienė, et al.. (2011). Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Journal of Immunological Methods. 373(1-2). 67–78. 38 indexed citations
5.
Klausz, Katja, Sven Berger, Jeroen J. Lammerts van Bueren, et al.. (2011). Complement‐mediated tumor‐specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science. 102(10). 1761–1768. 26 indexed citations
6.
Berger, Sven, Stefanie Derer, Katja Klausz, et al.. (2010). Fc‐engineered EGF‐R antibodies mediate improved antibody‐dependent cellular cytotoxicity (ADCC) against KRAS‐mutated tumor cells. Cancer Science. 101(5). 1080–1088. 37 indexed citations
7.
Peipp, Matthias, Joerg Bruenke, Michael Dechant, et al.. (2009). A Recombinant Bispecific Single-Chain Fragment Variable Specific for HLA Class II and FcαRI (CD89) Recruits Polymorphonuclear Neutrophils for Efficient Lysis of Malignant B Lymphoid Cells. The Journal of Immunology. 184(3). 1210–1217. 36 indexed citations
8.
Schneider‐Merck, Tanja, Jeroen J. Lammerts van Bueren, Sven Berger, et al.. (2009). Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage. The Journal of Immunology. 184(1). 512–520. 167 indexed citations
9.
Beyer, Thomas, Stefan Lohse, Sven Berger, et al.. (2009). Serum-free production and purification of chimeric IgA antibodies. Journal of Immunological Methods. 346(1-2). 26–37. 41 indexed citations
10.
Dechant, Michael, Sven Berger, Matthias Peipp, et al.. (2008). Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies. Cancer Research. 68(13). 4998–5003. 132 indexed citations
11.
Peipp, Matthias, Tanja Schneider‐Merck, Michael Dechant, et al.. (2008). Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations. The Journal of Immunology. 180(6). 4338–4345. 22 indexed citations
12.
Peipp, Matthias, Jeroen J. Lammerts van Bueren, Tanja Schneider‐Merck, et al.. (2008). Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood. 112(6). 2390–2399. 169 indexed citations
13.
Peipp, Matthias, Michael Dechant, & Thomas Valerius. (2008). Effector mechanisms of therapeutic antibodies against ErbB receptors. Current Opinion in Immunology. 20(4). 436–443. 40 indexed citations
14.
Dechant, Michael, Thomas Beyer, Tanja Schneider‐Merck, et al.. (2007). Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor. The Journal of Immunology. 179(5). 2936–2943. 75 indexed citations
15.
Renders, Lutz, Mike Ufer, Igor Mosyagin, et al.. (2006). CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients. Clinical Pharmacology & Therapeutics. 81(2). 228–234. 107 indexed citations
16.
Otten, Marielle A., Michael Dechant, Cornelis W. Tuk, et al.. (2005). Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors. The Journal of Immunology. 174(9). 5472–5480. 123 indexed citations
17.
Dechant, Michael, Gestur Vidarsson, Bernhard Stockmeyer, et al.. (2002). Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood. 100(13). 4574–4580. 69 indexed citations
18.
Stockmeyer, Bernhard, Michael Dechant, Roland Repp, et al.. (2001). Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies. Journal of Immunological Methods. 248(1-2). 103–111. 50 indexed citations
19.
Stockmeyer, Bernhard, Michael Dechant, Marjolein van Egmond, et al.. (2000). Triggering FCα-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy. The Journal of Immunology. 165(10). 5954–5961. 98 indexed citations
20.
Heijnen, Ingmar, Bernhard Stockmeyer, Heidi H. van Ojik, et al.. (1997). Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. The Journal of Immunology. 159(11). 5629–5639. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Ulrichts Breakdown of academic impact, for papers by Randall J. Brezski Breakdown of academic impact, for papers by Yvonne A. Efebera Breakdown of academic impact, for papers by DA Vallera Breakdown of academic impact, for papers by Kathy Schiffman Breakdown of academic impact, for papers by Paulo Vidal Campregher Breakdown of academic impact, for papers by Sandra Croockewit Breakdown of academic impact, for papers by Martha Hayden-Ledbetter Breakdown of academic impact, for papers by Robert Wasserman Breakdown of academic impact, for papers by Katrin Moser
Rankless by CCL
2026